Dotarem (gadoterate meglumine)
/ Guerbet
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
302
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
December 01, 2025
A new biocompatible amino-Gd-metallofullerenol (Amino-Gd-FulOH) nanoplatform as a potential MRI contrast agent and its effect on macrophages.
(PubMed, Biomed Pharmacother)
- "MRI analysis showed that amino-Gd-FulOH significantly enhanced T1-weighted signal intensity in macrophages compared to untreated controls, with a signal comparable to the clinical Gd-based agent Dotarem...While it modulates macrophage viability in dose-dependent manner, it preserves basic functions such as adhesion and migration. The combination of functional biocompatibility, rapid post-labeling clearance, and high imaging utility underscores its potential as a safe and effective theranostic compound, warranting further mechanistic exploration."
Journal • Oncology • RHOA • VCL
November 24, 2025
Dynamic contrast-enhanced magnetic resonance imaging for distinguishing vital and non-vital teeth in jaw lesions: a pilot study.
(PubMed, Oral Surg Oral Med Oral Pathol Oral Radiol)
- "Time-intensity curves derived from dynamic contrast-enhanced MRI accurately differentiated vital from non-vital teeth in jawbone lesions, comparable to the electric pulp test."
Journal
November 10, 2025
Ultrafast breast DCE-MRI: comparative analysis of semi-quantitative and pharmacokinetic parameters with gadoterate meglumine versus gadobutrol in malignant lesions and background parenchymal enhancement.
(PubMed, Quant Imaging Med Surg)
- "In ultrafast breast DCE-MRI, Gadavist demonstrated stronger early enhancement kinetics, whereas Dotarem provided improved tumor-to-BPE contrast and higher sensitivity for select kinetic parameters. These findings underscore the importance of tailoring contrast agent selection to specific diagnostic goals."
Journal • PK/PD data • Breast Cancer • Oncology • Solid Tumor
November 06, 2025
Gadoquatrane in Contrast-enhanced Head-and-neck and Liver Magnetic Resonance Imaging: A Preclinical Dose-Response Study in Pigs.
(PubMed, Invest Radiol)
- "The study suggests that gadoquatrane, which demonstrated signal-enhancement kinetics similar to those of gadobutrol and gadoterate meglumine, might be utilized effectively at a dose below 0.05 mmol Gd/kg body weight, independent of the anatomic structure investigated and the pulse sequence employed. Overall, the study supports and complements the results of the clinical dose-response study of gadoquatrane."
Journal • Preclinical
November 06, 2025
Aqueous-stable Mn(II)-MOF nanoparticles with high r1 relaxivity and biocompatibility: a novel T1 MRI contrast agent.
(PubMed, J Mater Chem B)
- "BVR-19-Mn exhibits a high r1 relaxivity of 4.98 mM-1 s-1 in water at 3 T and 25 °C, outperforming clinically approved gadolinium-based CAs such as Dotarem® under identical conditions...In vitro cytotoxicity and in vivo developmental zebrafish studies confirm biocompatibility across clinically relevant concentration ranges, with low toxicity observed at high dosing concentrations. Collectively, our findings position BVR-19-Mn as a high-performance MRI CA, introducing a sustainable, multifunctional platform for precision biomedical imaging."
Journal • Oncology • CAT
November 05, 2025
In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study.
(PubMed, Neurology)
- "Leakage of gadolinium-based contrast agent through the BBB can be measured in vivo in CAA from the leptomeningeal vessels, and findings point to likely leakage from cortical small vessels as well. Leakage from leptomeningeal vessels was associated with cSS. Studies with follow-up data need to determine whether these measures could serve as a predictive biomarker in CAA."
Journal • Observational data • Preclinical • Alzheimer's Disease • Cerebral Hemorrhage • CNS Disorders • Cognitive Disorders • Hematological Disorders
October 06, 2025
Cardiac Magnetic Resonance Imaging Derived Extracellular Volume Correlates with Reference Standard Measures of Ventricular Stiffness Derived from Pressure-Volume Loop Analysis in Single Right Ventricle Patients
(AHA 2025)
- "A Modified Look Locker sequence T1 mapping pre- and post-Dotarem was performed and offline processing was done in a blinded fashion (MyoMaps, Siemens Healthcare) (Figure 1)... The assessment of ECV in SRV patients is feasible. We found a good correlation between ECV and the reference standard measure of ventricular stiffness in ECV patients. Future studies should evaluate ECV's potential to identify SRV patients with stiffness abnormalities."
Clinical • MRI • Anesthesia • Cardiovascular • Fibrosis • Heart Failure • Immunology
November 03, 2025
Applying dual energy computed tomography to postmortem coronary computed tomographic angiography.
(PubMed, J Cardiovasc Comput Tomogr)
- "This study demonstrates the capacity of DECT to isolate lipophilic iodinated contrast from aqueous gadolinium contrast in the setting of ex vivo PMcCTA, allowing for simultaneous characterization of vascular patency and changes in myocardial perfusion associated with vessel obstruction or infarction."
Journal • Cardiovascular • Coronary Artery Disease • Myocardial Infarction
October 24, 2025
Tetrazine-trans-cyclooctene ligated lanthanide conjugates for biomedical imaging.
(PubMed, Inorg Chem Front)
- "The T 1 relaxivities of Gd(DO3A-tetrazine) and Gd(DO3A-PEG4-rhodamine) were found to be similar to [Gd(DOTA)]- (Dotarem®). As a proof-of-concept in vivo test, the click conjugates were delivered to mice brains using the combination of focused ultrasound and microbubbles, with neuron uptake of the probes observed."
Journal
October 13, 2025
Clinical application of gadoterate meglumine in abbreviated dynamic contrast-enhanced magnetic resonance imaging of the breast with ultrafast imaging: a single-center retrospective study.
(PubMed, Quant Imaging Med Surg)
- "Ktrans had the highest diagnostic sensitivity [98.3% (95% CI: 91.1-100%), P<0.05]. Based on quantitative pharmacokinetic analysis of ultrafast DCE-MRI, the study demonstrated the viability of utilizing Dotarem as an intravenous gadolinium-based contrast agent for DCE-MRI of the breast with preserved clinical success for breast cancer detection."
Journal • Retrospective data • Breast Cancer • Oncology • Solid Tumor
September 28, 2025
Leptomeningeal vascularity in Gadopiclenol Enhanced Pediatric Brain MRI.
(PubMed, AJNR Am J Neuroradiol)
- "Gadopiclenol increases background extra-axial enhancement on T1-weighted post-contrast sequences in pediatric brain MRI, likely reflecting its higher relaxivity. Radiologists should be aware of this effect to avoid misinterpretation as leptomeningeal pathology. Post-contrast FLAIR remains unaffected and continues to serve as a reliable sequence for detecting true meningeal disease."
Journal • Anesthesia • Pediatrics
September 04, 2025
Interaction study between gadolinium-based contrast agents and lysozyme using frontal analysis continuous capillary electrophoresis.
(PubMed, Anal Chim Acta)
- "FACCE is a well-adapted method to investigate GBCA-protein interaction. It requires low sample volumes and allows determining the stoichiometry, binding constant, and cooperativity of the interaction. This work emphasizes the cooperative nature of the GBCA-lysozyme interactions and indicates that the Hill model is suitable for analysing the interactions within the tested concentration range of GBCAs."
Journal
August 29, 2025
Prepubertal Exposure to Gadolinium-Based Contrast Agents Impairs Sperm Quality and Elevates Oxidative Stress in Adult Rats.
(PubMed, Toxicology)
- "Gadoteric Acid (Dotarem®) is approved for use in children of all ages, including neonates...Furthermore, increased oxidative stress markers and lipid peroxidation were observed in sperm and testicular tissue. A single prepubertal exposure to Gd, before the establishment of testicular and epididymal barriers, may lead to long-term alterations in sperm quantitative and qualitative parameters and induce oxidative stress in sperm and male reproductive tissues in adulthood."
Journal • Preclinical
August 19, 2025
The value of magnetic resonance imaging in the diagnosis of extraspinal osteoarticular brucellosis.
(PubMed, Medicine (Baltimore))
- "Thirty-nine patients diagnosed with brucellosis with corresponding joint pain admitted to our hospital from December 2020 to November 2021 were retrospectively analyzed as study subjects, and all of them underwent MRI, diffusion-weighted imaging, and gadoterate meglumine to observe the MRI imaging features of extraspinal osteoarthritic brucellosis and the affected joints...For abscess formation, by analyzing the joint cavity of the patient, the liquid signal shadow of T2 could be seen, and the lesion area showed noticeable uneven sheet enhancement in the enhanced scan. Extraspinal osteoarthritic brucellosis has specific characteristics in MRI, and MRI has significant clinical value in the diagnosis, differentiation, and evaluation of the therapeutic efficacy of this disease."
Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain
August 18, 2025
Evaluation of Gadoterate in Patients With Renal Dysfunction
(clinicaltrials.gov)
- P4 | N=46 | Terminated | Sponsor: Loyola University | Unknown status ➔ Terminated; The study was terminated by the Institutional Review Board
Trial termination • Nephrology • Renal Disease
August 18, 2025
Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease
(clinicaltrials.gov)
- P1 | N=16 | Terminated | Sponsor: Alzeca Biosciences, Inc. | Recruiting ➔ Terminated; A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment
Trial termination • Alzheimer's Disease • CNS Disorders
July 25, 2025
Dotarem vs Gadobutrol Contrast for Breast MRI
(clinicaltrials.gov)
- P4 | N=258 | Active, not recruiting | Sponsor: University of Massachusetts, Worcester | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025
Enrollment closed • Trial completion date • Trial primary completion date
August 16, 2025
Heavy metal complexes can induce structural changes and mineral redistribution in fruits: MRI and X-ray evidence
(ACS-Fall 2025)
- "Excess biometal extraction by these contrast agents generates weakly paramagnetic species evident from T1-type of MRI signal enhancement (T1 shortening) for Dotarem or localized T2 shortening (signal decrease) in susceptibility weighted imaging if higher Gd3+ loading is present as in Gadavist. This work indicates a new mechnistic pathway via transmetallation for seemingly safe MRI contrast agents and might raise health and environmental concerns."
Mood Disorders
August 05, 2025
Testicular varicocele embolization using CO2, gadolinium and lipiodol as contrast agents in a patient with an iodinated contrast allergy.
(PubMed, Radiol Case Rep)
- "After coil deployment the gadolinium-based contrast agent Dotarem, was injected and venography used to confirm occlusion of the left testicular vein...Due to their different properties, a combination of alternative contrast agents can be more effective than a single agent. We provide a pictorial review of the case and an educational summary on the indications and practical uses of various alternative contrast agents in IR procedures in a patient with a water-soluble iodinated contrast allergy."
Journal • Allergy • Anesthesia • Immunology • Pain
July 30, 2025
Identifying a potential role of immune cells in gadolinium deposition within the brain.
(PubMed, Fluids Barriers CNS)
- "Taken together, our in vitro observations show that immune cells can transport GBCA across the BBB and could lead to permanent deposition of Gd in the brain."
Journal • CD4 • CD8
July 29, 2025
In vivo 3D myocardial membrane potential mapping in humans using PET/MRI.
(PubMed, EJNMMI Res)
- "The proposed method allows 3D myocardial membrane potential mapping in humans in vivo."
Journal • Preclinical • Heart Failure
June 25, 2025
Dosimetric Evaluation of the Sensitivity of PAGAT Gel Dosimeters Infused with Clinically Used Gadolinium-Based Contrast Agents.
(PubMed, Gels)
- "This study evaluates the impact of gadolinium-based contrast agents (Omniscan, Dotarem, and Gadovist) on the performance of PAGAT gel dosimeters using spectrophotometric analysis...Additionally, gadolinium-infused PAGAT gels show strong potential for assessing dose enhancement phenomena. Their sensitivity, threshold behavior, and radiological properties suggest they may be suitable for applications in dose enhancement dosimetry as well as conventional clinical settings."
Journal
June 25, 2025
Gadopiclenol Versus Gadoterate Meglumine for Pediatric Brain MRI: An Intraindividual Comparison of Contrast Enhancement.
(PubMed, AJR Am J Roentgenol)
- " The findings support use of gadopiclenol at half the standard gadolinium dose for pediatric brain MRI examinations. Clinical Impact: Use of gadopiclenol could facilitate reductions in cumulative gadolinium exposure in children requiring serial MRI examinations."
Journal • Pediatrics
April 15, 2025
Renal perfusion assessment by magnetic resonance imaging in patients with diabetic cardiac autonomic neuropathy
(ERA 2025)
- "The contrast agent Dotarem (Gd-DOTA) was injected intravenously to enhance the visualisation of the kidneys, providing high-resolution images and quantifiable data on renal blood flow... This study investigated the impact of CAN on renal perfusion in individuals with type 1 and type 2 diabetes using DCE-MRI. The findings showed no significant differences in renal perfusion between 'no CAN' and 'CAN' group, challenging previous assumptions of its impact on renal perfusion due to sympathetic over activity. These outcomes highlight the need for future longitudinal studies with larger sample sizes."
Clinical • MRI • Acute Kidney Injury • Chronic Kidney Disease • Diabetic Nephropathy • Diabetic Neuropathy • Hepatology • Nephrology • Oncology • Pain • Renal Disease • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus
May 19, 2025
Overall Gadolinium Exposure Within the First 5 Months After Injection of Human Equivalent Doses of Gadopiclenol, Gadoterate, or Gadobutrol in Healthy Rats.
(PubMed, Invest Radiol)
- "Under our experimental conditions, the overall measured Gd exposure over 5 months following gadopiclenol injection in rats at the HED is 25-40% lower than that after gadoterate and gadobutrol injections, respectively."
Journal • Preclinical
1 to 25
Of
302
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13